- Home
- ACLX vs FOLD Comparison
ACLX vs FOLD Comparison
Compare ACLX & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- FOLD
- Stock Information
- Founded
- ACLX 2015
- FOLD 2002
- Country
- ACLX United States
- FOLD United States
- Employees
- ACLX N/A
- FOLD N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- ACLX Health Care
- FOLD Health Care
- Exchange
- ACLX Nasdaq
- FOLD Nasdaq
- Market Cap
- ACLX 3.3B
- FOLD 2.9B
- IPO Year
- ACLX 2022
- FOLD 2007
- Fundamental
- Price
- ACLX $57.55
- FOLD $5.98
- Analyst Decision
- ACLX Strong Buy
- FOLD Buy
- Analyst Count
- ACLX 14
- FOLD 10
- Target Price
- ACLX $109.33
- FOLD $16.22
- AVG Volume (30 Days)
- ACLX 715.8K
- FOLD 4.9M
- Earning Date
- ACLX 05-08-2025
- FOLD 05-01-2025
- Dividend Yield
- ACLX N/A
- FOLD N/A
- EPS Growth
- ACLX N/A
- FOLD N/A
- EPS
- ACLX N/A
- FOLD N/A
- Revenue
- ACLX $76,809,000.00
- FOLD $543,141,000.00
- Revenue This Year
- ACLX N/A
- FOLD $21.87
- Revenue Next Year
- ACLX $96.17
- FOLD $22.19
- P/E Ratio
- ACLX N/A
- FOLD N/A
- Revenue Growth
- ACLX N/A
- FOLD 28.25
- 52 Week Low
- ACLX $47.88
- FOLD $6.20
- 52 Week High
- ACLX $107.37
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- ACLX 42.15
- FOLD 28.44
- Support Level
- ACLX $47.86
- FOLD $5.82
- Resistance Level
- ACLX $67.36
- FOLD $7.71
- Average True Range (ATR)
- ACLX 4.20
- FOLD 0.31
- MACD
- ACLX -0.70
- FOLD -0.06
- Stochastic Oscillator
- ACLX 49.69
- FOLD 8.47
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.